Full text is available at the source.
The intestinal microbiota as a therapeutic target in the treatment of NAFLD and ALD
Using gut bacteria to help treat fatty liver disease and alcoholic liver disease
AI simplified
Abstract
The proportion of patients with nonalcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD) is growing globally.
- Liver diseases are prevalent worldwide, with a notable rise in NAFLD and ALD cases.
- Studies indicate a close relationship between intestinal microbiota and the development of NAFLD and ALD.
- Understanding the role of intestinal microbiota may enhance knowledge of the intestine-liver axis.
- Insights into the intestine-liver axis could lead to the development of novel therapies for liver diseases.
AI simplified